The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens

Shafiqur Rahman; Nichole M. Neugebauer; Zhenfa Zhang; Peter A. Crooks; Linda P. Dwoskin; Michael T. Bardo

doi:10.1016/j.ejphar.2008.10.037

The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens

Shafiqur Rahman
, Nichole M. Neugebauer
, Zhenfa Zhang
, Peter A. Crooks
, Linda P. Dwoskin
, Michael T. Bardo

Producción científica: Article › revisión exhaustiva

9 Citas (Scopus)

Resumen

The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.

Idioma original	English
Páginas (desde-hasta)	103-105
Número de páginas	3
Publicación	European Journal of Pharmacology
Volumen	601
N.º	1-3
DOI	https://doi.org/10.1016/j.ejphar.2008.10.037
Estado	Published - dic 28 2008

Nota bibliográfica

Funding Information:
This work was supported by USPHS grant U19 DA17548. For purposes of full disclosure, the University of Kentucky holds patents on bPiDDB and a potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.

Financiación

This work was supported by USPHS grant U19 DA17548. For purposes of full disclosure, the University of Kentucky holds patents on bPiDDB and a potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.

Financiadores	Número del financiador
National Institute on Drug Abuse	U19DA017548
U.S. Public Health Service	U19 DA17548

ASJC Scopus subject areas

Pharmacology

Acceder al documento

10.1016/j.ejphar.2008.10.037

Otros archivos y enlaces

Citar esto

@article{fe89e1d874864d98b113dc341dbb1dfc,

title = "The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens",

abstract = "The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.",

keywords = "DOPAC, Dopamine metabolism, HPLC, Nicotinic receptor, Nucleus accumbens, bPiDDB",

author = "Shafiqur Rahman and Neugebauer, \{Nichole M.\} and Zhenfa Zhang and Crooks, \{Peter A.\} and Dwoskin, \{Linda P.\} and Bardo, \{Michael T.\}",

note = "Funding Information: This work was supported by USPHS grant U19 DA17548. For purposes of full disclosure, the University of Kentucky holds patents on bPiDDB and a potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.",

year = "2008",

month = dec,

day = "28",

doi = "10.1016/j.ejphar.2008.10.037",

language = "English",

volume = "601",

pages = "103--105",

number = "1-3",

}

TY - JOUR

T1 - The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens

AU - Rahman, Shafiqur

AU - Neugebauer, Nichole M.

AU - Zhang, Zhenfa

AU - Crooks, Peter A.

AU - Dwoskin, Linda P.

AU - Bardo, Michael T.

N1 - Funding Information: This work was supported by USPHS grant U19 DA17548. For purposes of full disclosure, the University of Kentucky holds patents on bPiDDB and a potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.

PY - 2008/12/28

Y1 - 2008/12/28

N2 - The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.

AB - The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.

KW - DOPAC

KW - Dopamine metabolism

KW - HPLC

KW - Nicotinic receptor

KW - Nucleus accumbens

KW - bPiDDB

UR - https://www.scopus.com/pages/publications/56949098412

UR - https://www.scopus.com/pages/publications/56949098412#tab=citedBy

U2 - 10.1016/j.ejphar.2008.10.037

DO - 10.1016/j.ejphar.2008.10.037

M3 - Article

C2 - 19000671

AN - SCOPUS:56949098412

SN - 0014-2999

VL - 601

SP - 103

EP - 105

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1-3

ER -

The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto